Search research articles
Contact Us
Filters
Showing results (121-130 of 137) with videos related to
Page
of 14
Sort By:
Der Pathologe
|
February 14, 2019
[S3 guidelines on the diagnosis and treatment of carcinoma of the endometrium : Requirements for pathology]
L-C Horn, G Emons, S Aretz, et al.
Gynecologic Oncology
|
September 26, 2006
Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4
A R Günthert, S Ackermann, M W Beckmann, et al.
Cancer Research
|
November 15, 1993
High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines
G Emons, O Ortmann, M Becker, et al.
Cancer
|
October 1, 1996
Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group
G Emons, O Ortmann, H M Teichert, et al.
Cancer Research
|
February 15, 1995
Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma
G Irmer, C Bürger, R Müller, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology
|
March 18, 2004
Introital ultrasound of the lower genital tract before and after colposuspension: a 4-year objective follow-up
V Viereck, H-U Pauer, W Bader, et al.
International Journal of Oncology
|
October 13, 2000
Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines
S Westphalen, G Kotulla, F Kaiser, et al.
Molecular Psychiatry
|
July 1, 1997
Low leptin levels predict amenorrhea in underweight and eating disordered females
W Köpp, W F Blum, S von Prittwitz, et al.
The International Journal of Biological Markers
|
October 9, 2007
Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes
S Kümmel, H Eggemann, D Lüftner, et al.
Oncology (Williston Park, N.Y.)
|
February 3, 2005
Anthracycline and trastuzumab in breast cancer treatment
M Untch, I Himsl, S Kahlert, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 137) with videos related to
Sort By:
Page
of 14
Der Pathologe
|
February 14, 2019
[S3 guidelines on the diagnosis and treatment of carcinoma of the endometrium : Requirements for pathology]
L-C Horn, G Emons, S Aretz, et al.
Gynecologic Oncology
|
September 26, 2006
Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4
A R Günthert, S Ackermann, M W Beckmann, et al.
Cancer Research
|
November 15, 1993
High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines
G Emons, O Ortmann, M Becker, et al.
Cancer
|
October 1, 1996
Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group
G Emons, O Ortmann, H M Teichert, et al.
Cancer Research
|
February 15, 1995
Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma
G Irmer, C Bürger, R Müller, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology
|
March 18, 2004
Introital ultrasound of the lower genital tract before and after colposuspension: a 4-year objective follow-up
V Viereck, H-U Pauer, W Bader, et al.
International Journal of Oncology
|
October 13, 2000
Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines
S Westphalen, G Kotulla, F Kaiser, et al.
Molecular Psychiatry
|
July 1, 1997
Low leptin levels predict amenorrhea in underweight and eating disordered females
W Köpp, W F Blum, S von Prittwitz, et al.
The International Journal of Biological Markers
|
October 9, 2007
Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes
S Kümmel, H Eggemann, D Lüftner, et al.
Oncology (Williston Park, N.Y.)
|
February 3, 2005
Anthracycline and trastuzumab in breast cancer treatment
M Untch, I Himsl, S Kahlert, et al.
Page
of 14